Changchun GeneScience Pharmaceutical (GenSci), a subsidiary of Changchun High-Tech Industries (Group), recently held a groundbreaking ceremony for its new global headquarters and research & development (R&D) centre at Shanghai Zhangjiang International Medical Park.

With an increasing focus on women's and children's health, the Chinese government has been intensifying efforts to improve healthcare services for these demographics, embedding their care within the wider framework of the country's economic and social development policies.

The establishment of the R&D centre sets the stage for GenSci to further advance the convergence of industry, academia, research and the medical community. By leveraging cutting-edge R&D capabilities and the application of artificial intelligence technologies, GenSci is well-positioned to provide premium health solutions for women and children. 

The construction of this facility is progressing as planned, and it is expected to be fully operational by 2027, providing a capacity to accommodate up to 2,000 R&D professionals.

By 2025, the firm will boast an extensive portfolio, with the expectation of launching more than four top-tier innovative drugs and five novel medical devices annually in the years to come.